Journal Article

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Junko Tanizaki, Wooyoung Hur, Wenjun Zhou, Su-Jie Zhu, Peter S. Hammerman, Nathanael S. Gray, Dalia Ercan, Jing-Ruey Joanna Yeh, Jun Wang, Cai-Hong Yun, Amir R. Aref, David A. Barbie, Moosa Mohammadi, Rachel G. Liao, NamDoo Kim, Zhifeng Huang, Maria Rusan, Marzia Capelletti, Suzanne Gaudet, Li Tan, Pasi A. Jänne, Taebo Sim, Yiyun Zhang

2014

Overview

The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation. Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways. Preclinical studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clinically observed for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas. Here we report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors 2 (FIIN-2) and 3 (FIIN-3). To our knowledge, FIIN-2 and FIIN-3 are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clinical FGFR inhibitors such as NVP-BGJ398 and AZD4547. Because of the conformational flexibility of the reactive acrylamide substituent, FIIN-3 has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues. We report the cocrystal structure of FGFR4 with FIIN-2, which unexpectedly exhibits a “DFG-out” covalent binding mode. The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of FIIN-3 bound with FGFR4 V550L and EGFR L858R. These results have important implications for the design of covalent FGFR inhibitors that can overcome clinical resistance and provide the first example, to our knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket. Significance Inhibitors of the FGF receptors (FGFRs) are currently under clinical investigation for the treatment of various cancers. All currently approved kinase inhibitors eventually are rendered useless by the emergence of drug-resistant tumors. We used structure-based drug design to develop the first, to our knowledge, selective, next-generation covalent FGFR inhibitors that can overcome the most common form of kinase inhibitor resistance, the mutation of the so-called “gatekeeper” residue located in the ATP-binding pocket. We also describe a novel kinase inhibitor design strategy that uses a single electrophile to target covalently cysteines that are located in different positions within the ATP-binding pocket. These results have important implications for the design of covalent FGFR inhibitors that can overcome clinical resistance.

• Publisher: National Academy of Sciences,National Acad Sciences
• Subject: Adenosine triphosphatase / Amino Acid Substitution / Amino acids / Antineoplastic Agents - chemistry / Antineoplastic Agents - pharmacology / Binding Sites / Biological Sciences / Cell Line, Tumor / Crystallography, X-Ray / drug resistance / Drug Resistance, Neoplasm - drug effects / Drug Resistance, Neoplasm - genetics / drugs / ErbB Receptors - antagonists & inhibitors / ErbB Receptors - chemistry / ErbB Receptors - genetics / ErbB Receptors - metabolism / fibroblast growth factor receptors / Humans / Inhibitors / Kinases / Mutation / Mutation, Missense / neoplasms / Neoplasms - drug therapy / Neoplasms - enzymology / Neoplasms - genetics / Neoplasms - pathology / PNAS Plus / Protein Kinase Inhibitors - chemistry / Protein Kinase Inhibitors - pharmacology / Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors / Receptor, Fibroblast Growth Factor, Type 1 - chemistry / Receptor, Fibroblast Growth Factor, Type 1 - genetics / Receptor, Fibroblast Growth Factor, Type 1 - metabolism / Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors / Receptor, Fibroblast Growth Factor, Type 2 - chemistry / Receptor, Fibroblast Growth Factor, Type 2 - genetics / Receptor, Fibroblast Growth Factor, Type 2 - metabolism / Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors / Receptor, Fibroblast Growth Factor, Type 4 - chemistry / Receptor, Fibroblast Growth Factor, Type 4 - genetics / Receptor, Fibroblast Growth Factor, Type 4 - metabolism / Structure-Activity Relationship / T cell receptors